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Edited by Varda RotterAbstract The ampliﬁcation of hTERT was detected in glioma
tissues, although telomerase activity was not always found within
these specimens. The aim of this study was to correlate the level
of hTERT transcription with telomerase activity in two glioma
age groups. hTERT was signiﬁcantly transcribed at similar copy
numbers in both age groups. However, these mRNAs translated
to telomerase in 100% of the young compared to only 25% of the
older patients. While hTERT transcription correlated directly to
telomerase protein level and activity, as well as longer telomeres
in the young group, such correlations were missing in the older
group.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Glioma1. Introduction
During cell division, telomeric repeats are consistently lost
leading to a critical shortening of the telomere ensuring that
a cell has limited numbers of division [1–4]. The rate of cell loss
is balanced by the rate of cell renewal in normal cell cycles,
however, with aging, the rate of cell loss will exceed the rate
of cell renewal [5]. Telomerase reactivation enables cells that
are destined to senescence to confer replicative immortality
without aﬀecting other regulatory systems [6,7]. Hence cancer
cells are able to proliferate unrestricted by maintaining telo-
mere length either by the reactivation of telomerase [8] or alter-
native lengthening of telomeres (ALT) [9]. The presence of
ALT in glioblastoma was found to correlate with long term
survival [10]. However, approximately 90% of tumour cells
succeed by acquiring the expression of telomerase [11,12]. Tel-
omerase activity was detected in the diﬀerent grades of glio-
mas, whilst none was found within the normal brain
specimens [13].
The ampliﬁcation of hTERT, telomerase catalytic subunit,
was detected in glioma cell lines and primary tumours and
was suggested to correlate with the expression of telomerase
directly [14]. In addition, hTERT mRNA was found to co-
localize not only in carcinoma regions but also in benign tu-
mour and these expression patterns are correlated with the in-
crease severity of the histopathologic changes [15]. However,*Corresponding author. Fax: +44 0 1772892929.
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doi:10.1016/j.febslet.2008.04.027previous results from our lab detected hTERT mRNA in gli-
oma tissues lacking telomerase activity [16]. The aim of this re-
search is to evaluate the correlation between hTERT
transcription, telomerase activity and telomerase length in
two glioma age groups.2. Materials and methods
2.1. Tissue sample
Tumour samples were obtained from glioma cancer patients, admit-
ted to the Royal Preston Hospital, UK. Control material was obtained
from patients who required resection of normal brain for purposes
other than primary glioma treatment. Written consent was granted
prior to the tissues being used in this investigation. Brain samples were
surgically dissected and frozen immediately in liquid nitrogen prior to
the assay. Tissues used in the investigation included: a recurrent ana-
plastic astrocytoma, an anaplastic oligoastrocytoma III, a anaplastic
oligodendroglioma III, a progressive ganglioma IV, eight glioblasto-
mas and two normal brain samples.
2.2. hTERT and GAPDH transcription
mRNA was isolated from all tissues using mRNA isolation Kit
(Roche, UK). Isolated mRNA (100 ng tissue) was transcribed to
cDNA using a First strand cDNA Synthesis Kit (Roche, UK) which
was used as a template for qRT-PCR.
Quantitative real time PCR was carried out to determine the expres-
sion of hTERT (214 bp) and GAPDH (238 bp, glyceraldehyde-3-phos-
phate dehydrogenase as a control) using Fast Start DNA masterPLUS
SYBR Green 1 (Roche, UK). The PCR primer sequences speciﬁc for
all the variants of hTERT mRNA were 5 0CGTGGTTTCTG-
TGTGGTGTC 3 0 (sense) and 5 0CCTTGTCGCCTGAGGAGTAG
3 0 (antisense) and for GAPDH primers were 5 0GAGTCAACGGAT-
TTGGTCGT 3 0 (sense) and 5 0TTGATTTTGGAGGGATCTCG 3 0
(antisense). After an initial denaturation at 95 C for 10 min, the sam-
ples were subjected to 35 cycles of RT-PCR (95 C for 10 s, annealing
temperature 67 C (hTERT) and 55 C (GAPDH) for 15 s, and 72 C
for 15 s). PCR reactions were performed in triplicate and a negative
control (no DNA) was included [16].
2.3. Telomerase activity assay (TRAPeze)
Telomerase activity was performed by Telomeric Repeat Ampliﬁca-
tion Protocol (TRAP) assay (Chemicon International, USA) according
to the manufacturers protocol. Cells (106) were lysed in CHAPS lysis
buﬀer (200 ll). After incubation on ice for 30 min, the lysate was cen-
trifuged at 12000 · g for 20 min at 4 C. The supernatant from each
extract (500 ng of protein) was subjected to the TRAP assay. A pre-
incubation at 30 C for 30 min was carried out to allow telomerase-
mediated extension of the substrate oligonucleotide before the ex-
tended products were ampliﬁed by 33 cycles of PCR (94 C for 30 s,
59 C for 30 s, and 72 C for 1 min).
2.4. Telomere length assay
DNA extracted from tissue sample using FastDNA kit (Q BIOgene,
UK) was subjected to the TeloTAGGG Telomere length assay (Roche)
according to the manufacturers protocol. Genomic DNA (3 lg) wasblished by Elsevier B.V. All rights reserved.
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hexanucleotide repeats (Hinf1 and Rsa1). The digested DNA was then
loaded on a 0.8% agarose gel and electrophoresed for approximately
2.5 h at 5 V/cm. The DNA was transferred, hybridized with the telo-
mere speciﬁc digoxigenin (DIG)-labelled hybridization probe, incu-
bated with antialkaline phosphatase before the chemiluminescence
signal was detected using Molecular Imager ChemiDoc XRS System,
(Biorad, UK).
2.5. Immunoﬂuorescence
A 3 lm slice was cut from each tissue FFPE block. Tissue slides were
deparaﬃnised and re-hydrated before antigen retrieval was performed
in a microwave for 20 min. The slides were then washed with TBS plus
0.025% triton (TBS-T) for 10 min, before the blocking solution was
added (10% goat serum with 1% BSA in TBS) for 2 h at room temper-
ature. The blocking solution was discarded and monoclonal primary
telomerase antibody (1:2000) (Abcam, UK) was applied to the tissues
and incubated overnight at 4 C with gentle agitation. The slides were
rinsed twice in TBS-T before light sensitive FITC conjugated second-
ary antibody (Sigma, UK) was applied and incubated for 1 h at RT.
The slides were washed three times in TBS, counter stained with VEC-
TASHIELD (1.5 lg/ml) mounting medium with propidium iodide
(PI, Vector, USA) for 10 min to allow nuclear stain and the tissue
slides were visualised. Cells were visualised and scanned using Axiovert
200M LSN 510 laser scanning confocal microscope (Carl Zeiss Ltd.,
UK).
2.6. Statistical analyses
Students two-tailed t-test for studies on mRNA copies, protein
quantiﬁcation, telomerase activity and telomere length were carried
out using SPSS 13.0 for Windows. Values were expressed as the
means ± S.D., values of P < 0.05 were considered to be statistically sig-
niﬁcant.3. Results
Human gliomas and two normal brain tissue in two age
groups (20–39 and 40–70 years) (Table 1) were used to assess
the transcriptional levels of hTERT and GAPDH (the house
keeping gene as a reference) using qRT-PCR (Fig. 1).
In order to measure all the variants of hTERT mRNA, spe-
ciﬁc PCR primer sequences were used in this study. hTERT,
the rate-limiting component for telomerase activity, was signif-
icantly transcribed in all glioma tissues and was absent in the
brain control tissues (P = 0.001). No signiﬁcant diﬀerences
were observed in the transcription of hTERT between the dif-
ferent glioma age groups. Similarly, no signiﬁcant diﬀerences
in GAPDH transcription was observed between cancer and
normal tissues (P = 0.357) (Fig. 1).Table 1
List of tissues used and a summary of the results in ascending order of age
Diagnosis Age Gender hTERT mRNA/1
1 Glioblastoma 23 F 298
2 Progressive ganglioglioma IV 28 F 312
3 Recurrent anaplastic ependymona 34 F 319
4 Glioblastoma 38 M 310
5 Glioblastoma 46 F 305
6 Anaplastic oligodendroglioma III 56 M 308
7 Glioblastoma 60 F 298
8 Anaplatic oligoastrocytoma III 62 F 286
9 Glioblastoma 62 M 307
10 Glioblastoma 63 M 300
11 Glioblastoma 64 M 311
12 Glioblastoma 67 F 308
13 Normal 38 F 1
14 Normal 66 M 1Telomerase protein levels were quantiﬁed as a percentage of
telomerase positive cells per sample (a total of 250 cells were
counted per sample) (Fig. 1). There was a signiﬁcant diﬀerence
in protein level between cancers and normal tissues
(P = 0.001). Telomerase protein was detected in four of four
young patients and in two of eight older patients. Telomerase
activity was measured using the TRAPeze method. While, tel-
omerase activity was detected in the glioma tissues that ex-
pressed telomerase protein, it was not detected in tissues
lacking telomerase. As expected, there was neither hTERT
expression, neither telomerase activity in the normal brain tis-
sues (Figs. 1 and 2).
Telomere length was measured in tissues used for the study,
which ranged between 11.5 and 16.3 kbp in the young cancer
patients and 6.1 and 10.1 kbp in the older cancer patients.
For the normal patients, the length ranged from 7.4 to
9.5 kbp. A signiﬁcant diﬀerence in telomere length was ob-
served between young and old cancer patients (P = 0.002),
and young cancer patient verses normal patient (P = 0.02).
However, there was no signiﬁcant diﬀerence between older
cancer patient and normal patient (P = 0.817). Moreover,
there is a correlation between telomerase activity and telomere
length in young glioma patients, but there was no such corre-
lation observed in the older glioma patients. Although there
was telomerase activity in one of the 67-year-old glioma pa-
tient, telomere length was similar to tissues possessing no telo-
merase activity. A summary of the results are presented in
Table 1.4. Discussion
Telomerase regulation can be achieved either by the tran-
scriptional regulation of hTER and hTERT or post-transcrip-
tional alternative splicing of hTERT [9]. Our results showed
that there is no detectable hTERT mRNA in the human brain
tissues, which correlated with the lack of telomerase activity.
This suggests that the regulation of telomerase activity occurs
at the transcriptional level of hTERT.
Competitive RT-PCR data indicated that most cancer cells
contains 1–30 molecules of hTERT mRNA per cell with a rel-
atively long half-life of 2–3 h [17].
Intriguingly, all glioma tissues used in this study regardless
















Fig. 1. Gene expression of hTERT and GAPDH together with telomerase protein levels in 14 brain tissue samples. (A) Agarose gel electrophoresis:
Lanes 1–8 amplicons from glioblastoma tissues, Lane 9–12 amplicons from recurrent anaplastic ependymoma, anplastic oligoastrocytoma III, an
anaplastic oligodendroglioma III, a progressive ganglioglioma IV, respectively and Lanes 13 and 14 represent the amplicons from the normal brain
tissues. (B) Telomerase protein levels assessed using immunoﬂuorescence in each corresponding tissue. Green: Telomerase antigen detected with
FITC conjugate secondary antibody; red; nuclei labelled with propidium iodide. The percent represent the number of positive cells within the sample.
The sample size is 500 cells (data values are mean ± S.D., n = 3).
Fig. 2. Telomerase activity and telomere length in tissues. (A)
Telomerase activity: Lanes 1–8 represent glioblastoma tissues, Lane
9–12 recurrent anaplastic ependymoma, anplastic oligoastrocytoma
III, an anaplastic oligodendroglioma III, a progressive ganglioglioma
IV, respectively and Lanes 13 and 14 represent the normal brain
tissues. Lane 15 telomerase positive cells, Lane 16 CHAPS Lysis buﬀer
negative control, Lane 17, the 20 bp molecular marker (36 bp marker
as an internal control). (B) Telomere lengths: Lanes 1 and 18 represent
the DIG M.Wt marker, Lane 2 DNA control high, Lane 3 DNA
control low, Lanes 4–17 represent telomere length from the respective
tissues as in (A).
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tissues). However, the mRNA translated to telomerase in four
of four (100%) of the young age compared to only two of eight
(25%) of the older age tissues. This suggests that the down-reg-
ulation of telomerase protein expression in some of these tis-
sues is not due to the lack of hTERT gene transcription or
its promoter methylation, but possibly due to post-transcrip-
tional or post-translational mechanisms.
A previous study showed that 32 of 33 tested renal cancer
tissues expressed hTERT mRNA, hence only 27 of these tis-
sues concomitantly expressed telomerase activity [18]. How-
ever, unlike our ﬁnding, hTERT mRNA was expressed at
various levels and there was a correlation between the mRNA
and telomerase activity. In addition, no correlation between
telomerase activity and age was observed [18].
Variant hTERT mRNA splicing may produce non-func-
tional forms; however, the extent to which hTERT mRNA
splicing variance control telomerase activity in human cancers
is controversial [17]. The distribution among the alternate
splicing forms in telomerase positive cell types are strikingly
similar, suggesting that the distribution among these forms is
determined by common mechanisms in tumour cells that do
not change signiﬁcantly with tissue origin [17]. Moreover,
hTERT mRNA splicing is not involved in the regulation of en-
zyme activity [19].
Two cases in this study within the older glioma age group
exhibited a discrepancy between hTERT gene expression and
telomerase activity. In addition, one case within the same
age group exhibited a discrepancy between telomerase activity
and telomere length. However, no such discrepancy was ob-
served in the younger age group. Additional studies using a
large cohort of glioma tissues are needed to further our under-
standing of the exact mechanisms for this results in the glioma
older age group. Cases exhibiting hTERT gene transcription
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hTERT mRNA may represent an earlier event than the reacti-
vation of telomerase enzyme in tumourigenesis [20]. Most can-
cer cells activate telomerase to elongate telomeres and achieve
unlimited replicative potential. Interestingly, some cancer cells
cannot activate telomerase and use telomere homologous
recombination to ALT to elongate telomeres [9,21,22].
The hallmark question then if cells do not translate hTERT
mRNA in certain age groups then why transcribing such a
large number in cancer cell only? Could it be that these mole-
cules can activate tumourigenesis via an alternative route in
addition to the telomerase reactivation?
Evidence has suggested that telomerase contributes to tumo-
urigenesis independent of its role in telomere maintenance
[23,24].
The results suggest that additional modes of telomerase reg-
ulation act at as yet undeﬁned levels, which may include trans-
lational and/or post-translational mechanisms and may be
inﬂuenced by age. The question of whether telomerase activity
is controlled at various stages of life by hTERT mRNA alone
and/or by additional interacting proteins remains to be an-
swered.
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